PARIS - Acticor Biotech, a clinical-stage biotechnology company, has published the results of its phase 1b/2a ACTIMIS study in The Lancet Neurology Journal, demonstrating the safety of its drug glenzocimab in acute ischemic stroke (AIS) patients. The study showed that glenzocimab, when used with standard thrombolysis treatment, reduced the incidence of symptomatic intracranial hemorrhage to 0% from 10% and all-cause mortality to 8% from 21% in comparison to a placebo.
The ACTIMIS trial focused on the combination of glenzocimab with reference treatments such as thrombolysis with or without thrombectomy in AIS patients. The results suggest that patients with severe strokes, who are at a higher risk of intracranial hemorrhage, might benefit the most from the treatment.
Coordinating Investigator for ACTIMIS and first author of the manuscript, Professor Mikaël Mazighi, commented on the significance of the findings, highlighting the potential of glenzocimab to pave the way for new treatments in the acute phase of ischemic stroke. Dr. Yannick Pletan, Chief Medical Officer of Acticor Biotech, noted the study's contribution to understanding the dual action of glenzocimab in reducing intracranial hemorrhages and mortality.
The results, initially presented at the European Stroke Organisation Conference (ESOC) in 2022, have been further supported by a post-hoc analysis using artificial intelligence to assess brain imaging. This independent analysis confirmed a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab.
Acticor Biotech is now focusing on the ACTISAVE phase 2/3 clinical trial, which completed recruitment in October 2023, with results expected in the second quarter of 2024. The company has been granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in stroke treatment, facilitating early dialogues with regulatory authorities.
This news is based on a press release statement from Acticor Biotech, a company listed on Euronext Growth Paris under the ticker FR0014005OJ5 - ALACT.
InvestingPro Insights
As Acticor Biotech progresses with its clinical trials for glenzocimab, investors and stakeholders are keeping a close eye on the company's financial health and market performance. With a market capitalization of 40.49 million USD and a notably high Price / Book ratio of 96.79 as of the last twelve months ending Q2 2023, the company's valuation metrics are intriguing. Despite these challenging valuations, the stock has shown a positive one-week price total return of 5.94%.
Acticor Biotech's financials reveal some concerns, as highlighted by the InvestingPro Tips. The company is quickly burning through cash and has been operating with a moderate level of debt. Additionally, it has not been profitable over the last twelve months, with an operating income of -18.19 million USD. Analysts do not anticipate the company will turn a profit this year, which aligns with the reported negative Return on Assets of -145.59%. These factors could be crucial for investors considering the long-term prospects of the company's stock, which often moves counter to the market trend.
For those looking to delve deeper into Acticor Biotech's financials and market potential, InvestingPro offers additional insights. Subscribers can access a comprehensive list of tips, including the company's cash burn rate and gross profit margins. Take advantage of the special New Year sale with discounts of up to 50% on an InvestingPro subscription. Use coupon code SFY24 for an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 for an additional 10% off a 1-year subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.